Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

[1]  K. Hongo,et al.  Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. , 2015, Journal of neurosurgery.

[2]  X. Gu,et al.  Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis , 2015, Scientific Reports.

[3]  小林 正学.  Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy : a multicenter analysis , 2015 .

[4]  Shanshan Jiang,et al.  Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer , 2015, Oncotarget.

[5]  A. Kargi,et al.  Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[6]  Takashi Kurata,et al.  Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature. , 2015, Cytotherapy.

[7]  Y. Shibamoto,et al.  Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report , 2014, World Journal of Surgical Oncology.

[8]  K. Silay,et al.  A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer , 2014, PloS one.

[9]  Jun Zhao,et al.  Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2014, Journal of cancer research and therapeutics.

[10]  Y. Shibamoto,et al.  The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer , 2014, Journal of Ovarian Research.

[11]  D. Costa,et al.  EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients , 2014, Targeted Oncology.

[12]  Y. Takeda,et al.  Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.

[13]  S. Ramalingam,et al.  Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Y. Shibamoto,et al.  Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer , 2013, Journal of Gastrointestinal Surgery.

[15]  M. Yıldız,et al.  Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[16]  S. Tsujitani,et al.  Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. , 2013, European journal of cancer.

[17]  Juhua Luo,et al.  Predictors of survival in patients with non-small cell lung cancer. , 2012, Oncology nursing forum.

[18]  S. Attaran,et al.  A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  A. Santoro,et al.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Yonemitsu,et al.  Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma , 2012, Pancreas.

[21]  J. Vassallo,et al.  Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study , 2011, Journal of experimental & clinical cancer research : CR.

[22]  T. Lam,et al.  Lower lung cancer mortality in obesity. , 2011, International journal of epidemiology.

[23]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[24]  N. Saijo,et al.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Jett,et al.  A prognostic model for advanced stage nonsmall cell lung cancer , 2006, Cancer.

[26]  C. Figdor,et al.  Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Schlom,et al.  Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules , 2005, Clinical Cancer Research.

[28]  J. Whang‐Peng,et al.  A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late‐stage lung carcinoma , 2005, Cancer.

[29]  S. Akira,et al.  Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation , 2004, Cancer Research.

[30]  E. Hirschowitz,et al.  Autologous dendritic cell vaccines for non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Menzies,et al.  Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.

[32]  S. Akira,et al.  Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. , 2003, Journal of the National Cancer Institute.

[33]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[34]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[35]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[36]  K. Gatter,et al.  Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[38]  M. Dogan,et al.  Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[39]  W. Guo,et al.  Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. , 2014, Cancer biomarkers : section A of Disease markers.